Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

219.72 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

October 09, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

2 Growth Stocks That Could Rocket Higher Before the End of 2023 ↗

October 08, 2023

Potential approvals of new medicines expected soon could push these stocks through the roof.

Via The Motley Fool

Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023

October 06, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analyst Expectations for Alnylam Pharmaceuticals's Future ↗

September 29, 2023

Via Benzinga

What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗

September 12, 2023

Via Benzinga

The Latest Analyst Ratings for Alnylam Pharmaceuticals ↗

August 16, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 05, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Analyst Expectations for Alnylam Pharmaceuticals's Future ↗

July 25, 2023

Via Benzinga

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects ↗

September 14, 2023

On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.

Via Benzinga

Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer ↗

September 14, 2023

Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug.

Via Investor's Business Daily

Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease ↗

September 14, 2023

On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran.

Via Benzinga

Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going ↗

September 14, 2023

US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data.

Via Benzinga

Topics Economy Stocks

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

September 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Buy List Alert: 3 Pharma Stocks with Positive Trial Updates ↗

September 13, 2023

These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.

Via InvestorPlace

Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

September 13, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗

September 11, 2023

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 08, 2023

Via Benzinga

Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public' ↗

September 08, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time,

Via Benzinga

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗

September 07, 2023

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,

Via Benzinga

Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

September 07, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

3 Stocks to Buy For the COVID Resurgence

September 06, 2023

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

Via MarketBeat

Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today ↗

September 05, 2023

Via Benzinga

Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against Moderna

August 25, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity

August 03, 2023

From Alnylam Pharmaceuticals

Via Business Wire

Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference

August 02, 2023

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗

July 31, 2023

Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key

Via Benzinga

Lululemon Athletica To Rally Around 12%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

July 25, 2023

Needham raised the price target for F5, Inc. (NASDAQ: FFIV) from $175 to $180. Needham analyst Alex Henderson maintained a Buy rating. F5 shares jumped 11.2% to $167.00 in pre-market trading.

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.